Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Nippon Kayaku Gets Japan Commercial Rights to Anheart’s ROS1 Inhibitor
Nippon Kayaku has obtained the exclusive rights to market and distribute AnHeart Therapeutics’ ROS1 tyrosine kinase inhibitor taletrectinib in Japan for US$40 million upfront. The drug is being developed for the treatment of ROS1-positive non-small cell lung cancer (NSCLC). The…
To read the full story
Related Article
- ROS1 Drug Effective in Japanese Subgroup: Nippon Kayaku
November 5, 2024
BUSINESS
- Parexel Revs Up AI Drive, Targets 6-Month Trial Time Cut
October 8, 2026
- FDA Accepts BridgeBio’s Infigratinib NDA for Achondroplasia
October 8, 2026
- Eylea 8 mg Shows Vision Gains in 24-Week Analysis
October 8, 2026
- Boehringer, Hiroshima Tie Up on Health Promotion
October 8, 2026
- Japan Ethical Drug Sales Up 3% in August: Crecon
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…